Clinical trial • Phase I/II • Infectious Disease|Other

CD40.Pan.CoV vaccine for Healthy volunteers

Phase I/II trial of CD40.Pan.CoV vaccine for Healthy volunteers. 48 participants.

Overview

Trial Therapeutic Area
Infectious Disease|Other
Trial Disease
Healthy volunteers
Trial Stage
Phase I/II
Drug Modality
Vaccine

Key dates

Initial CTIS Submission Date
17-12-2024
First CTIS Authorization Date
25-04-2025

Trial design

Phase I/II trial across 7 sites in France.

Target Sample Size
48

Recruitment

Planned Sample Size
48
Recruitment Window Months
22

Geography

Total Number Of Sites
7
Total Number Of Participants
48

France

Earliest CTIS Part Ii Submission Date
31-01-2025
Latest Decision Or Authorization Date
23-03-2026
Processing Time Days
416
Number Of Sites
7
Number Of Participants
48

Sites

Site Name
Hopital Saint Louis
Department Name
CIC1427
Contact Person Name
Juliette SORET DULPHY
Contact Person Email
juliette.soret@aphp.fr
Site Name
Centre Hospitalier Universitaire De Caen Normandie
Department Name
Centre de recherche clinique
Contact Person Name
Renaud VERDON
Contact Person Email
verdon-r@chu-caen.fr
Site Name
CHU Henri Mondor
Department Name
Service d'immunologie clinique et maladies infectieuses
Contact Person Name
Jean Daniel LELIEVRE
Contact Person Email
jean-daniel.lelievre@aphp.fr
Site Name
University Hospital Of Clermont-Ferrand
Department Name
CIC1405
Contact Person Name
Christian DUALE
Contact Person Email
cduale@chu-clermontferrand.fr
Site Name
Centre Hospitalier Universitaire De Nantes
Department Name
CIC1413
Contact Person Name
Maeva LEFEBVRE
Contact Person Email
maeva.lefebvre@chu-nantes.fr
Site Name
Centre Hospitalier Universitaire De Lille
Department Name
CIC 14036 Institut Coeur Poumon
Contact Person Name
Dominique DEPLANQUE
Site Name
Hôpital Cochin
Department Name
CIC 1417 Cochin Pasteur
Contact Person Name
Odile LAUNAY
Contact Person Email
odile.launay@aphp.fr

Sponsor

Primary sponsor

Full Name
ANRS Maladies Infectieuses Emergentes
Organisation Type
Laboratory/Research/Testing facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
CD40.Pan.CoV vaccine
Modality
Vaccine

Related trials

Other published trials that may interest you.